MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
uniQure N.V. Retained Earnings 2011-2026 | QURE
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings uniQure N.V.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.13 B | -890 M | -582 M | -455 M | -785 M | -660 M | -536 M | -475 M | -396 M | -276 M | -220 M | -199 M | -155 M | -137 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -137 M | -1.13 B | -493 M |
Quarterly Retained Earnings uniQure N.V.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.29 B | -1.21 B | -1.17 B | -1.13 B | -1.06 B | -1.01 B | -956 M | -890 M | -817 M | -728 M | -659 M | -582 M | -589 M | -541 M | -502 M | -455 M | -463 M | -427 M | -826 M | -785 M | -785 M | -785 M | -785 M | -660 M | -660 M | -660 M | -660 M | -536 M | -536 M | -536 M | -536 M | -475 M | -475 M | -475 M | -475 M | -396 M | -396 M | -396 M | -396 M | -323 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -323 M | -1.29 B | -676 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M |  Canada |
 |
Adagene
ADAG
|
-311 M | $ 1.9 | -3.11 % | $ 107 M |  China |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K |  USA |
 |
AgeX Therapeutics
AGE
|
-131 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.71 | 1.88 % | $ 17 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
569 M | $ 25.87 | -0.79 % | $ 1.25 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.31 | -4.06 % | $ 7.96 B |  Australia |
 |
Aptose Biosciences
APTO
|
-541 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
-616 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
AVROBIO
AVRO
|
-477 M | - | 1083.1 % | $ 745 M | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-972 M | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Brickell Biotech
BBI
|
-172 M | - | -5.38 % | $ 6.06 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-278 M | $ 2.97 | 3.12 % | $ 908 M |  Israel |
 |
BeiGene, Ltd.
BGNE
|
-8.61 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-611 M | $ 215.29 | 4.59 % | $ 5 B |  Danmark |
 |
BioNTech SE
BNTX
|
-410 M | $ 105.97 | -2.78 % | $ 27.2 B | Germany |
 |
Bellicum Pharmaceuticals
BLCM
|
-575 M | - | -9.72 % | $ 5.89 M | USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Bio-Path Holdings
BPTH
|
-108 M | - | - | $ 100 K | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
 |
Baudax Bio
BXRX
|
-191 M | - | 0.59 % | $ 63 K | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
-1.63 B | $ 64.74 | 1.41 % | $ 8.66 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-166 M | $ 3.96 | -1.0 % | $ 8.62 B | Israel |
 |
CASI Pharmaceuticals
CASI
|
-606 M | $ 0.95 | -0.72 % | $ 129 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
-1.02 B | - | -15.15 % | $ 60.3 M | Britain |
 |
Celldex Therapeutics
CLDX
|
-1.56 B | $ 25.15 | -1.95 % | $ 1.62 M | USA |
 |
AIkido Pharma
AIKI
|
-223 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-715 M | - | 4.14 % | $ 49.1 M | USA |
 |
Catalyst Biosciences
CBIO
|
-85.5 M | $ 14.01 | 3.7 % | $ 922 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
Biogen
BIIB
|
19.3 B | $ 164.87 | 0.27 % | $ 24 B | USA |
 |
Avid Bioservices
CDMO
|
-572 M | - | - | $ 789 M | USA |
 |
BioVie
BIVI
|
-352 M | $ 1.23 | 2.07 % | $ 1.82 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
285 M | $ 23.32 | 2.71 % | $ 2.76 B | USA |
 |
Calithera Biosciences
CALA
|
-491 M | - | -10.95 % | $ 876 K | USA |